BENTAMAN® 25
Bendamustine HCl 25 mg

BENTAMAN® 100
Bendamustine HCl 100 mg

Lyophilised Injection

Argentine Industry - Dispense under prescription

Qualitative and quantitative composition:

Each Bentaman® 25 glass bottle contains:
Bendamustine HCl 25.0 mg
Mannitol 42.5 mg

Each Bentaman® 100 glass bottle contains:
Bendamustine HCl 100.0 mg
Mannitol 170 mg

Therapeutic action: 

Antineoplasic agent

Therapeutic indications:

Chronic lymphocytic leukaemia (CLL)
Bentaman is indicated for the treatment of patients with chronic lymphocytic leukaemia. The efficacy of primary therapies other than chlorambucil has not been established.

Non-Hodgkin’s lymphoma (NHL)
Bentaman lyophilised injection is indicated for the treatment of patients with indolent B-cell non-Hodgking lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regime.

Marketed presentations:

Bentaman® 25 lyophilised injection: cartons containing one amber 14-ml glass bottle.Bentaman 100 lyophilised injection: cartons containing one amber 50-ml glass bottle.

Storage:

Store at room temperature (below 30°C) inside the marketed packing.

Medicinal speciality authorised by the Ministry of Health.
Certificate Nº 56692

Laboratorio DOSA S.A. 
Girardot 1369 (C1427AKC) City of Buenos Aires, Argentina.
Pharmaceutical Director: María C. Terzo, Pharmacist.